JOP20200260B1 - مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث - Google Patents

مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Info

Publication number
JOP20200260B1
JOP20200260B1 JOJO/P/2020/0260A JOP20200260A JOP20200260B1 JO P20200260 B1 JOP20200260 B1 JO P20200260B1 JO P20200260 A JOP20200260 A JO P20200260A JO P20200260 B1 JOP20200260 B1 JO P20200260B1
Authority
JO
Jordan
Prior art keywords
menopausal symptoms
compounds
component
relieving
relieving menopausal
Prior art date
Application number
JOJO/P/2020/0260A
Other languages
English (en)
Inventor
Glwadys Rausin
Marie Mawet
Maud Jost
Melanie Taziaux
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66440001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200260(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of JOP20200260A1 publication Critical patent/JOP20200260A1/ar
Application granted granted Critical
Publication of JOP20200260B1 publication Critical patent/JOP20200260B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

يتعلق الاختراع الحالي بعلاج بالهرمونات البديلة والمركبات ووحدات التعبئة المرتبطة به للتخفيف من الأعراض المصاحبة لانقطاع الطمث والتي تعتمد على إعطاء كائن ثديي أنثوي مكون استيترول بجرعات يومية محددة. واختياريًا، يمكن أن يتم ذلك، بالاتحاد مع مكون بروجستيروني. كما يتمتع العلاج بفاعلية ذات دلالة إحصائية مقترنة بشاكلة مفضلة للآثار الجانبية مقارنة بالطرق المتاحة حاليًا للتخفيف من الأعراض المصاحبة لانقطاع الطمث.
JOJO/P/2020/0260A 2018-04-19 2020-10-12 مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث JOP20200260B1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18168234 2018-04-19
EP18174985 2018-05-30
EP19150421 2019-01-04
PCT/EP2019/060221 WO2019202142A1 (en) 2018-04-19 2019-04-19 Compounds and their uses for alleviating menopause-associated symptoms

Publications (2)

Publication Number Publication Date
JOP20200260A1 JOP20200260A1 (ar) 2020-10-12
JOP20200260B1 true JOP20200260B1 (ar) 2025-10-01

Family

ID=66440001

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2020/0260A JOP20200260B1 (ar) 2018-04-19 2020-10-12 مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Country Status (38)

Country Link
US (2) US11484539B2 (ar)
EP (2) EP4056185A1 (ar)
JP (1) JP7309853B2 (ar)
KR (1) KR102765432B1 (ar)
CN (1) CN111989105B (ar)
AU (1) AU2019254681B2 (ar)
BR (1) BR112020021205A2 (ar)
CA (1) CA3097240A1 (ar)
CL (1) CL2020002711A1 (ar)
CO (1) CO2020012606A2 (ar)
CR (1) CR20200486A (ar)
CU (1) CU20200074A7 (ar)
DK (1) DK3781171T3 (ar)
EC (1) ECSP20066233A (ar)
ES (1) ES2909703T3 (ar)
GE (2) GEP20227396B (ar)
HR (1) HRP20220312T1 (ar)
IL (1) IL278155B (ar)
JO (1) JOP20200260B1 (ar)
LT (1) LT3781171T (ar)
MD (1) MD3781171T2 (ar)
MX (2) MX2020011014A (ar)
MY (1) MY206921A (ar)
NI (1) NI202000069A (ar)
NZ (1) NZ768774A (ar)
PE (1) PE20211588A1 (ar)
PH (1) PH12020551697A1 (ar)
PL (1) PL3781171T3 (ar)
PY (1) PY1930813A (ar)
RS (1) RS62954B1 (ar)
SG (1) SG11202009725XA (ar)
SI (1) SI3781171T1 (ar)
SM (1) SMT202200130T1 (ar)
TW (1) TWI805742B (ar)
UA (1) UA128428C2 (ar)
UY (1) UY38188A (ar)
WO (1) WO2019202142A1 (ar)
ZA (1) ZA202006407B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57328B1 (sr) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
NZ737945A (en) 2015-06-18 2023-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CR20200486A (es) 2018-04-19 2021-01-27 Estetra Sprl Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
EP4440541A1 (en) * 2021-11-29 2024-10-09 Estetra SRL Compositions for preventing or treating skin aging
US12233074B2 (en) 2022-02-10 2025-02-25 Estetra Srl Contraceptive methods with improved pearl index
EP4637781A1 (en) * 2023-02-23 2025-10-29 Estetra SRL Composition comprising estetrol and drospirenone for use in relieving and treating pain
CN119112905A (zh) * 2024-09-10 2024-12-13 武汉九珑人福药业有限责任公司 含雌孕激素的药物组合物、药物制剂及其制备方法、应用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
CA2011063C (en) 1989-02-28 1999-07-06 Calum B. Macfarlane Nicardipine pharmaceutical composition for parenteral administration
JPH03237557A (ja) 1990-02-14 1991-10-23 Oki Electric Ind Co Ltd ニューラルネットワークシミュレータ及び計算機システム
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
US6706700B2 (en) 1999-12-02 2004-03-16 Akzo-Nobel, N.V. 14β,15β-methylene-17α-hydroxymethyl-androgens
IL150775A0 (en) 2000-01-18 2003-02-12 Schering Ag Drospirenone for hormone replacement therapy
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
DE60217324T2 (de) 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
WO2002094277A1 (en) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Means and method for hormonal contraception
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
ATE254465T1 (de) 2001-05-23 2003-12-15 Pantarhei Bioscience Bv Zubereitungen für die hormonale kontrazeption
US7732430B2 (en) 2001-05-23 2010-06-08 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
EP1390041B1 (en) 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ATE347365T1 (de) * 2001-11-15 2006-12-15 Pantarhei Bioscience Bv Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
CA2476940C (en) 2002-02-21 2011-11-01 Bayer Intellectual Property Gmbh Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
AU2003274946A1 (en) 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
CA2489270C (en) 2002-06-11 2012-08-07 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
US9034854B2 (en) 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
MXPA05002294A (es) 2002-08-28 2005-09-12 Casper Robert Regimen de sustitucion de estrogeno.
US8987240B2 (en) 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
ES2338781T3 (es) 2002-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Uso de la drospirenona para el tratamiento de una hipertension.
AU2003279624A1 (en) 2002-11-08 2004-06-07 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
JP2006525306A (ja) 2003-04-30 2006-11-09 デビオファーム ソシエテ アノニム ゴナドトロピン・ホルモン放出ホルモンを使用する方法及び組成物
DK1624878T3 (da) 2003-05-22 2007-01-08 Pantarhei Bioscience Bv Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte
EP2409690B1 (en) 2003-09-29 2022-11-09 Novo Nordisk Health Care AG Improved stability of progestogen formulations
PL1670440T3 (pl) 2003-09-29 2014-11-28 Novo Nordisk Healthcare Ag Preparaty HRT
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
PT1755562E (pt) 2004-05-28 2013-12-26 Richter Gedeon Nyrt Contraceptivo contendo ácido fólico
EA013211B1 (ru) 2004-07-01 2010-04-30 Лек Фармасьютиклз Д.Д. Быстрораспадающаяся диспергирующаяся во рту лекарственная форма и способ ее приготовления
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
IS7724A (is) 2005-03-02 2006-09-03 Actavis Group Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1888615B1 (en) 2005-05-26 2012-05-16 Abbott Products GmbH 17 -hsd1 and sts inhibitors
KR20080031037A (ko) 2005-06-29 2008-04-07 와이어쓰 결합형 에스트로겐과 바제독시펜의 제형
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
EP1971344B1 (en) 2006-01-09 2010-09-22 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
ES2558030T3 (es) 2006-03-02 2016-02-01 Warner Chilcott Company, Llc Método anticonceptivo oral multifásico de ciclo prolongado
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
ES2659316T3 (es) 2006-06-08 2018-03-14 Allergan Pharmaceuticals International Limited Procedimientos para administrar formas de dosificación sólidas de etinilestradiol y profármacos del mismo con biodisponibilidad mejorada
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE112007001600A5 (de) 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CN101541326A (zh) 2006-11-29 2009-09-23 惠氏公司 雌激素/选择性雌激素受体调节剂（serm）和雌激素/孕酮双层药片
ES2531929T3 (es) 2006-12-20 2015-03-20 Teva Women's Health, Inc. Formas de dosificación solidas que se disgregan en la boca que comprenden progestina y métodos para hacer y usar las mismas
CN101583363B (zh) 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
KR20090104862A (ko) 2007-01-12 2009-10-06 와이어쓰 정제내 정제 조성물
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
US8367647B2 (en) 2007-06-21 2013-02-05 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
WO2009011576A1 (en) 2007-07-19 2009-01-22 Pantarhei Bioscience B.V. Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation
FR2920311B1 (fr) 2007-08-31 2010-06-18 Galenix Innovations Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation
JP5399749B2 (ja) 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
PT2262486E (pt) 2008-08-01 2013-03-27 Tovarna Zdravil D D Novo Mesto Krka Composição de quetiapina
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
CN101780073B (zh) 2009-01-21 2013-07-03 重庆圣华曦药业股份有限公司 非布司他分散片药物及其制备方法
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
JP2012521393A (ja) 2009-03-26 2012-09-13 ロイヤル カレッジ オブ サージェオンズ イン アイルランド 口腔内分散性錠剤
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
KR20120044307A (ko) 2009-06-23 2012-05-07 바이엘 파마 악티엔게젤샤프트 긴급 피임용 제약 조성물
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
MX356702B (es) 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
CL2013003435A1 (es) 2011-06-01 2014-08-01 Estetra Sprl Proceso de preparacion de intermediarios de estetrol utilizando catalizadores de paladio y grupos protectores acilantes o sililantes; y uso de dicho proceso para preparar estetrol.
BR112013030833B1 (pt) 2011-06-01 2019-09-03 Estetra S A processo para a preparação de um composto de fórmula (i) e processo para a preparação de estetrol
WO2012164096A1 (en) 2011-06-01 2012-12-06 Estetra S.A. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HUE025350T2 (en) 2011-07-19 2016-02-29 Pantarhei Bioscience Bv Tablets containing dehydroepiandrosterone (DHEA)
BR112014003113A2 (pt) 2011-08-11 2017-03-14 Estetra Sprl método de contracepção de emergência em uma fêmea mamífero
BR112014005134A2 (pt) 2011-09-16 2017-04-18 Ferring Bv composição farmacêutica de dissolução rápida
EP2764008B1 (en) 2011-10-07 2016-08-17 Estetra S.P.R.L. Process for the production of estetrol
WO2013090117A1 (en) 2011-12-13 2013-06-20 Arstat, Inc. A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
US9238265B2 (en) 2012-09-27 2016-01-19 General Electric Company Backstrike protection during machining of cooling features
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
JP6126456B2 (ja) 2013-05-17 2017-05-10 東和薬品株式会社 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
EP3943079A1 (en) 2013-05-21 2022-01-26 Predictive Therapeutics, LLC Therapeutic and method of use
EP3046928B1 (en) 2013-09-18 2017-02-08 Crystal Pharma, S.A.U. Process for the preparation of estetrol
HUE035848T2 (en) 2013-12-12 2018-05-28 Donesta Bioscience B V Solid dispensing unit containing an estetrol compound in the mouth
US10571371B2 (en) 2014-08-07 2020-02-25 Wake Forest University Health Sciences Compositions and methods for clearing a biological sample
ES2957543T3 (es) 2014-09-29 2024-01-22 Univ California Composiciones y métodos para mantener la función cognitiva
CA2986039A1 (en) 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
RS57328B1 (sr) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
NZ737945A (en) 2015-06-18 2023-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
WO2016203044A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
DK3313408T3 (da) 2015-06-23 2024-01-29 Laboratorios Leon Farma Sa Drospirenon-baseret svangerskabsforebyggende middel til en kvindelig patient, som lider af overvægt
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
CA3178291A1 (en) * 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CA3041016C (en) 2016-10-28 2023-09-05 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
UA126746C2 (uk) 2018-02-07 2023-01-18 Естетра Спрл Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CR20200486A (es) 2018-04-19 2021-01-27 Estetra Sprl Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
US10929286B2 (en) 2018-06-29 2021-02-23 Seagate Technology Llc Arbitrated management of a shared non-volatile memory resource
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Also Published As

Publication number Publication date
NI202000069A (es) 2021-03-23
AU2019254681A1 (en) 2020-10-29
EP4056185A1 (en) 2022-09-14
PL3781171T3 (pl) 2022-05-23
UA128428C2 (uk) 2024-07-10
PH12020551697A1 (en) 2021-07-19
ZA202006407B (en) 2022-06-29
MY206921A (en) 2025-01-17
CN111989105B (zh) 2024-07-19
CO2020012606A2 (es) 2021-01-18
SI3781171T1 (sl) 2022-04-29
TWI805742B (zh) 2023-06-21
GEAP202215476A (en) 2022-03-25
IL278155A (en) 2020-11-30
SMT202200130T1 (it) 2022-05-12
TW202011968A (zh) 2020-04-01
BR112020021205A2 (pt) 2021-01-19
CN111989105A (zh) 2020-11-24
KR20210005039A (ko) 2021-01-13
US20230025785A1 (en) 2023-01-26
NZ768774A (en) 2024-12-20
EP3781171B1 (en) 2022-02-09
JP7309853B2 (ja) 2023-07-18
IL278155B (en) 2021-07-29
WO2019202142A1 (en) 2019-10-24
PE20211588A1 (es) 2021-08-18
LT3781171T (lt) 2022-04-11
US20210154212A1 (en) 2021-05-27
CA3097240A1 (en) 2019-10-24
CL2020002711A1 (es) 2020-12-28
ECSP20066233A (es) 2020-11-30
JOP20200260A1 (ar) 2020-10-12
CU20200074A7 (es) 2021-05-12
US11484539B2 (en) 2022-11-01
DK3781171T3 (da) 2022-05-02
KR102765432B1 (ko) 2025-02-12
RS62954B1 (sr) 2022-03-31
UY38188A (es) 2019-10-01
MD3781171T2 (ro) 2022-04-30
MX2020011014A (es) 2021-01-29
ES2909703T3 (es) 2022-05-10
JP2021522321A (ja) 2021-08-30
CR20200486A (es) 2021-01-27
MX2023001705A (es) 2023-04-03
HRP20220312T1 (hr) 2022-05-13
EP3781171A1 (en) 2021-02-24
PY1930813A (es) 2020-07-14
SG11202009725XA (en) 2020-11-27
AU2019254681B2 (en) 2024-08-08
GEP20227396B (en) 2022-07-25

Similar Documents

Publication Publication Date Title
JOP20200261A1 (ar) مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
MX2023001705A (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia.
CL2015002485A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
BR112017028048A2 (pt) drospirenona como o único ingrediente contraceptivo para uso
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX2020011295A (es) Tratamiento de dermatitis atopica.
CO2019000604A2 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d
ZA201906153B (en) Pharmaceutical compositions for combination therapy
CY1125177T1 (el) Χημικες ενωσεις και οι χρησεις τους για την ανακουφιση των συμπτωματων της εμμηνοπαυσης
EA202092267A1 (ru) Соединения и пути их применения для облегчения симптомов, связанных с менопаузой
EA202092224A1 (ru) Соединения и пути их применения для облегчения симптомов, связанных с менопаузой
TH2001005862A (th) องค์ประกอบสำหรับบรรเทาอาการโซมอเตอร์ที่เกี่ยวโยงกับภาวะหมดประจำเดือน
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
AR114799A1 (es) Compuestos y sus usos para aliviar los síntomas relacionados con la menopausia
MX2016011801A (es) Crema de estradiol de dosis baja.
AR114798A1 (es) Compuestos y sus usos para aliviar los síntomas relacionados con la menopausia
UA100902U (uk) Спосіб лікування мікрогландулярної гіперплазії шийки матки у жінок із порушеннями вегетативного гомеостазу
UA100789U (uk) Спосіб лікування пацієнток з аномальними матковими кровотечами на тлі антикоагуляційної терапії
UA97018U (uk) Спосіб лікування урогенітальних інфекцій у жінок з порушенням репродуктивної функції
UA87456U (uk) Спосіб лікування запальних захворювань зовнішніх статевих органів у жінок на фоні вторинного імунодефіциту